Orasure Tech Stock Price, News & Analysis

OraSure Technologies has secured a $109 million contract from the U.S. Department of Defense to enhance production capacity for its InteliSwab™ COVID-19 rapid tests. This initiative aims to bolster the nation’s pandemic preparedness, expanding manufacturing by 100 million tests annually by March 2024. The InteliSwab test, which detects active COVID-19 infections, has received multiple Emergency Use Authorizations from the FDA. The contract supports domestic industrial expansion for critical medical resources.

OraSure Technologies (NASDAQ: OSUR) has secured up to $13.6 million in funding from the Biomedical Advanced Research Development Authority (BARDA) to obtain 510(k) clearance and CLIA waiver for its InteliSwab™ COVID-19 rapid test. This test allows self-collection and provides results within 30 minutes without the need for lab equipment. The company holds three Emergency Use Authorizations (EUAs) from the FDA for different uses of the test, which is crucial for COVID-19 containment strategies. Full regulatory clearance is anticipated to ensure the test's long-term availability.

OraSure Technologies (NASDAQ: OSUR) announced a $205 million procurement contract with the Defense Logistics Agency for the InteliSwab™ COVID-19 Rapid Test, aimed at over-the-counter use. This contract will supply tests to approximately 25,000 U.S. sites from October 2021 to September 2022, funded by the federal government. InteliSwab™ offers a simple self-collection method and provides results in 30 minutes without the need for instruments. The company anticipates significant manufacturing and operating expenses related to this contract and expects the majority of revenue to be recognized in 2022.

OraSure Technologies (NASDAQ: OSUR) announced CFO Roberto Cuca will resign effective September 17, 2021, to pursue another healthcare opportunity. The company is seeking a permanent CFO, evaluating both internal and external candidates. Scott Gleason, SVP of Investor Relations and Corporate Communications, will serve as interim CFO. CEO Stephen Tang expressed confidence in the company’s outlook, citing increased demand for its InteliSwab™ COVID-19 Rapid Test and the recovery of core businesses.

OraSure Technologies announced strong financial performance for Q2 2021, with net revenues of $57.6 million, a 97% increase YoY. Excluding COVID-19 product sales, revenues grew 122% YoY, signaling a return to pre-pandemic levels. The company received FDA Emergency Use Authorizations for its InteliSwab™ COVID-19 Rapid Tests and signed distribution agreements with two major U.S. distributors. With cash reserves of $229.4 million, the company anticipates third-quarter revenues between $45 million and $50 million, projecting total revenues of approximately $230 million for FY 2021.

OraSure Technologies (NASDAQ: OSUR) is set to release its 2021 second quarter financial results on August 3, 2021, at 4:01 p.m. ET. The company will host a conference call at 5:00 p.m. ET to discuss these results and significant business developments.

Participants can join the call by dialing (888) 771-4371 for domestic access or (847) 585-4405 internationally, using Conference ID #50205303. The live Webcast will be accessible on OraSure's Investor Relations page, with a replay available for 14 days post-call.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in diagnostic tests and specimen collection devices, announced Dr. Stephen S. Tang's participation in the Raymond James 2021 Human Health Innovation Conference. Scheduled for June 23, 2021, at 11:20 AM EDT, the event will be webcast live, accessible via OraSure Technologies' website. A replay will also be available for 14 days. OraSure is committed to enhancing health and wellness with its innovative diagnostic solutions offered globally across various healthcare sectors.

OraSure Technologies collaborates with the Will Rodgers Liver Health Foundation to raise awareness about Hepatitis C (HCV) in the U.S. Approximately 2.4 million Americans have HCV, with over half unaware of their infection. The partnership aims to promote testing, as untreated HCV can lead to severe liver conditions. The OraQuick® HCV rapid antibody test, offering results in 20 minutes, is central to the initiative. This effort aligns with the foundation's mission to educate and support communities affected by liver disease, enhancing early diagnosis and treatment access.

OraSure Technologies has received Emergency Use Authorization (EUA) from the FDA for its InteliSwab™ COVID-19 Rapid Test. This rapid antigen test allows users to detect active COVID-19 infections easily and is available for Over-the-Counter (OTC) use. The testing process requires no special instruments, provides results in 30 minutes, and boasts strong clinical performance with 84% agreement on positive results versus PCR tests. OraSure aims to increase production capacity from 55 million to 70 million units annually by Q3 2021. However, it anticipates limited revenue from InteliSwab™ in Q2 2021 due to updating labeling requirements.